Organon (OGN) Income from Continuing Operations (2020 - 2026)

Organon (OGN) posted quarterly Income from Continuing Operations of 146000000.0 for Q1 2026, up 67.82% year-over-year from 87000000.0 in Q1 2025, and up 171.22% on a QoQ basis from 205000000.0 in Q4 2025.

Organon (OGN) Income from Continuing Operations (2020 - 2026) Analysis & Trends

Organon (OGN) has reported Income from Continuing Operations for 7 consecutive years, with 146000000.0 the latest figure, recorded in Q1 2026.

  • In Q1 2026, Income from Continuing Operations rose 67.82% year-over-year to 146000000.0; the TTM figure through Mar 2026 stood at 246000000.0 (down 67.2% YoY), while the FY2025 annual figure was 187000000.0, down 78.36% from the prior year.
  • Income from Continuing Operations came in at 146000000.0 for Q1 2026 at Organon, up from 205000000.0 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 546000000.0 in Q4 2023, with the low at 205000000.0 in Q4 2025.
  • Average Income from Continuing Operations over 5 years is 210000000.0, with a median of 195000000.0 recorded in 2024.
  • Across the five-year window, Income from Continuing Operations jumped 518.97% in 2024 and slumped 288.07% in 2025, its largest moves.
  • Year by year, Income from Continuing Operations stood at 541000000.0 in 2022, then grew by 0.92% to 546000000.0 in 2023, then sank by 80.04% to 109000000.0 in 2024, then plunged by 288.07% to 205000000.0 in 2025, then jumped by 171.22% to 146000000.0 in 2026.
  • According to Business Quant data, Income from Continuing Operations over the past three periods registered 146000000.0, 205000000.0, and 160000000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn 7.40 Bn
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn 5.24 Bn
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn 697.00 Mn
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn 833.00 Mn
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn -4.21 Bn
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn 1.82 Bn
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn 2.02 Bn
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn 2.71 Bn
9 Novartis Ag 113.45 Bn 113.67 Bn - -
10 Organon 3.53 Bn 2.41 Bn 783.00 Mn 146.00 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 146.00 Mn
Dec 31, 2025 -205.00 Mn
Sep 30, 2025 160.00 Mn
Jun 30, 2025 145.00 Mn
Mar 31, 2025 87.00 Mn
Dec 31, 2024 109.00 Mn
Sep 30, 2024 359.00 Mn
Jun 30, 2024 195.00 Mn
Mar 31, 2024 201.00 Mn
Dec 31, 2023 546.00 Mn
Sep 30, 2023 58.00 Mn
Jun 30, 2023 242.00 Mn
Mar 31, 2023 177.00 Mn
Dec 31, 2022 541.00 Mn
Sep 30, 2022 227.00 Mn
Jun 30, 2022 234.00 Mn
Mar 31, 2022 348.00 Mn
Dec 31, 2021 202.00 Mn
Sep 30, 2021 323.00 Mn
Jun 30, 2021 431.00 Mn